Standard BioTools Inc.
Standard BioTools Inc. is classed by the SEC under Laboratory Analytical Instruments (industry code 3826), based in Boston, MA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $85 million and a loss of $75 million (its filed statements).
vs its business-model standard
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 3826, Laboratory Analytical Instruments); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 3.4 out of ten, 8 of 9 metrics filed and 1 estimated: past 1.4 out of ten, present 3.4 out of ten, future 5.3 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
- Surviving crises (past): 1.5 out of ten. 3 warning events since 2017; the latest 2026-07-24. 15th percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Track record (past): 1.6 out of ten. -2.2% a year over 10 filed years; profitable in 0 of 10. 16th percentile among 21 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Shareholder treatment (past): 0.7 out of ten. CrossAssetData estimate 0.7/10, confidence 35 of 100 (one part). 7th percentile among 21 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
- Financial health (present): 4.4 out of ten. ROE -18%: lost 18¢ per shareholder dollar. Leverage 25%: owes 25¢ per asset dollar. 44th percentile among 22 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Industry position (present): 3.0 out of ten. bottom 30% of 21 in its family; net margin -87.8%. 30th percentile among 21 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Leadership (present): 2.1 out of ten. bottom 21% of 21 in its family for leadership; chief executive since 2022. 21st percentile among 21 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
- Room to expand (future): 4.9 out of ten. bottom 49% of 21 in its family for room to expand. 49th percentile among 21 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Growth drivers (future): 5.1 out of ten. top 49% of 21 in its family for growth drivers. 51st percentile among 21 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Expectations vs reality (future): 6.4 out of ten. top 36% of 20 in its family for expectations against reality. 64th percentile among 20 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-03-16 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-05 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-05 (on EDGAR). Newest filing: Form S-4/A, 2026-10-09. Filings on record since 2002. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: Consumables 43%, Instruments 30%, Services and Other Revenue 28%. By geography: EMEA 42%, Americas 36%, Asia Pacific 22%. As tagged in its annual report (Form 10-K, filed 2026-03-16).
Who runs it
Egholm, Michael (President & CEO); Kim, Hanjoon Alex (Chief Financial Officer); Mackay, Sean (SVP & Chief Business Officer); Carey, Thomas D. (director); Casdin, Eli (director); Cox, Troy (director); Eloi, Fenel M (director); Hibbs, Kathy L (director); Witney, Frank (director); Casdin, Capital, Llc (director); and 6 more. 16 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
This file: Overview · Past · Present · Future · Filings · every company on file
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.